ICD-10 Specific code M09.2: Juvenile arthritis in ulcerative colitis

Specific codes in ICD-10 are unique alphanumeric designations used to identify and categorize diseases, disorders, and conditions. They consist of 3-5 characters, including both letters and numbers, that provide a high level of detail and specificity.

Translations

Language Translation
Flag for English language  English Juvenile arthritis in ulcerative colitis
Flag for French language  French Polyarthrite juvรฉnile au cours de colite ulcรฉreuse (K51.-)

Hierarchical position

Level Code Title
1 XIII Diseases of the musculoskeletal system and connective tissue
2 M05-M14 Inflammatory polyarthropathies
3 M09 Juvenile arthritis in diseases classified elsewhere
4 M09.2 Juvenile arthritis in ulcerative colitis

Indicated medicines

Active Ingredient Description
Abatacept

Abatacept is a fusion protein that consists of the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc portion of human immunoglobulin G1 (IgG1). Abatacept selectively modulates a key costimulatory signal required for full activation of T lymphocytes expressing CD28.

Acetylsalicylic acid

Acetylsalicylic acid combines significant advantages such as strong anti-pyretic, analgesic and anti-inflammatory action, that is the measure of comparison with all the newer NSAIDs.

Adalimumab

Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 0.1-0.2 nM).

Etanercept

Etanercept is a competitive inhibitor of TNF binding to its cell surface receptors, and thereby inhibits the biological activity of TNF. The mechanism of action of etanercept is thought to be its competitive inhibition of TNF binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF biologically inactive.

Golimumab

Golimumab is a human monoclonal antibody that forms high affinity, stable complexes with both the soluble and transmembrane bioactive forms of human TNF-ฮฑ, which prevents the binding of TNF-ฮฑ to its receptors.

Hydroxychloroquine

Hydroxychloroquine is a antimalarial agent with have several pharmacological actions which may be involved in their therapeutic effect in the treatment of rheumatic disease, but its role is not known.

Naproxen

Naproxen is a non-steroidal anti-inflammatory analgesic compound with antipyretic properties as has been demonstrated in classical animal test systems. Naproxen exhibits its anti-inflammatory effect even in adrenalectomised animals, indicating that its action is not mediated through the pituitary-adrenal axis.

Triamcinolone

Triamcinolone acetonide is a more potent derivative of triamcinolone and is approximately 8 times more potent than prednisone. Although the precise mechanism of corticosteroid anti-allergic action is unknown, corticosteroids are very effective in the treatment of allergic diseases in man. Also, local injections are thought to have an anti-inflammatory effect.